Clicky

Immunic, Inc.(IMUX) News

Date Title
May 9 Immunic, Inc. (NASDAQ:IMUX) Q1 2024 Earnings Call Transcript
May 9 We Think Immunic (NASDAQ:IMUX) Needs To Drive Business Growth Carefully
May 8 Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 1 Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal
May 1 Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update
Apr 30 Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation
Apr 29 Immunic CEO Dr Daniel Vitt marks International Day of Immunology with discussion on its crucial role
Apr 4 With 44% ownership, Immunic, Inc. (NASDAQ:IMUX) has piqued the interest of hedge funds investors
Apr 4 Immunic to Host MS R&D Day and Participate in Investor Conferences in April
Mar 21 Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month
Mar 21 Immunic secures key patent, boosting MS drug exclusivity and global IP strategy
Mar 20 Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States
Mar 8 Immunic to reveal promising MS treatment data in two poster presentations at ACTRIMS Forum 2024
Mar 7 Immunic to Participate in Investor and Scientific Conferences in March
Jan 5 Immunic Highlights 2023 Accomplishments and Upcoming Milestones
Jan 5 Immunic, Inc. Announces Private Placement of up to $240 Million
Nov 7 Immunic to Announce Financial Results for the Third Quarter Ended September 30, 2023, and Provide Corporate Update
Oct 4 Immunic to Participate in Scientific Conferences in October
Jun 27 These 2 ‘Strong Buy’ Penny Stocks Could Soar to $25 (Or Higher), Says Piper Sandler
Jun 27 Pleasing Signs As A Number Of Insiders Buy Immunic Stock